{"id":53217,"date":"2024-05-18T00:43:15","date_gmt":"2024-05-18T00:43:15","guid":{"rendered":"https:\/\/news.talkwithrattan.com\/index.php\/2024\/05\/18\/after-covishield-its-covaxin-adverse-effects-covaxin-users-may-face-bhu-study-on-covaxin-raises-alarm\/"},"modified":"2024-05-18T00:43:15","modified_gmt":"2024-05-18T00:43:15","slug":"after-covishield-its-covaxin-adverse-effects-covaxin-users-may-face-bhu-study-on-covaxin-raises-alarm","status":"publish","type":"post","link":"https:\/\/news.talkwithrattan.com\/index.php\/2024\/05\/18\/after-covishield-its-covaxin-adverse-effects-covaxin-users-may-face-bhu-study-on-covaxin-raises-alarm\/","title":{"rendered":"After Covishield, it’s Covaxin: Adverse effects Covaxin users may face – BHU study on Covaxin raises alarm"},"content":{"rendered":"
\"After<\/div>


\n<\/p>\n

\n

\n
<\/div>\n
\n

1<\/span>\/<\/span>7<\/span><\/p>\n

BHU study on Covaxin raises alarm<\/h2>\n<\/div>\nA one-year follow-up study by a team of researchers at BHU revealed that nearly one-third of 926 recipients of Bharat Biotech’s anti-Covid vaccine, Covaxin, reported “adverse events of special interest,” or AESI. The researchers called for an extended surveillance of COVID-19-vaccinated individuals to understand the course and outcomes of late-onset AESIs, given the majority of AESIs persisting for a significant period.<\/caption>\n

ANI<\/p>\n<\/section>\n

\n
\"Stroke<\/div>\nSerious AESI, which included stroke and Guillain-Barre syndrome, were reported in one per cent of individuals, the study conducted by researchers from the Banaras Hindu University (BHU), which looked at long-term safety of the BBV152 (Covaxin) vaccine in adolescents and adults, claimed. Guillain-Barre syndrome is an autoimmune disorder which causes weakness in nerves in arms and legs.<\/caption>\n

iStock<\/p>\n

<\/section>\n

\n
\"Skin,<\/div>\n
\n

3<\/span>\/<\/span>7<\/span><\/p>\n

Skin, nerves and body affected<\/h2>\n<\/div>\n“Close to one-third of the individuals developed AESIs. New-onset skin and subcutaneous disorders, general disorders, and nervous system disorders were the three most common disorders observed in adolescents after receiving the vaccine,” the study said.<\/caption>\n

iStock<\/p>\n<\/section>\n

\n
\"Most<\/div>\n
\n

4<\/span>\/<\/span>7<\/span><\/p>\n

Most common effects of Covaxin<\/h2>\n<\/div>\nNew-onset skin and subcutaneous disorders (10.5%), general disorders (10.2%), and nervous system disorders (4.7%) were the common AESIs in adolescents. General disorders (8.9%), musculoskeletal disorders (5.8%), and nervous system disorders (5.5%) were the common AESIs in adults.<\/caption>\n

iStock<\/p>\n<\/section>\n

\n
\"Menstrual<\/div>\n
\n

5<\/span>\/<\/span>7<\/span><\/p>\n

Menstrual abnormalities observed too<\/h2>\n<\/div>\nMenstrual abnormalities were noticed in 4.6% of female participants. Ocular abnormalities and hypothyroidism were observed in 2.7 per cent and 0.6 per cent of participants.<\/caption>\n

iStock<\/p>\n<\/section>\n

\n
\"Deaths<\/div>\nFour deaths (three female individuals, one male individual) were reported in adults, the study added. All four had diabetes, while hypertension in three, and a history of pre-vaccination COVID-19 was present in two of them. Stroke was the main contributor in two deaths and one fatality was due to post-COVID-19 rhinocerebral mucormycosis, which supposedly disseminated after vaccination as reported by the caregivers. The fourth death happened in a woman with multiple episodes of unconsciousness post-vaccination, the etiology of which remained unidentified till death. In the absence of a definite causality association, no conclusions can be drawn from these events, the study said.<\/caption>\n

iStock<\/p>\n<\/section>\n

\n
\"Bharat<\/div>\n
\n

7<\/span>\/<\/span>7<\/span><\/p>\n

Bharat Biotech’s retort<\/h2>\n<\/div>\nHowever, Bharat Biotech in a statement in response to the study, said, “several studies have been executed on the safety of Covaxin, and published in peer-reviewed journals, demonstrating an excellent safety track record”. The study involved 635 adolescents and 291 adults, who received the BBV152 vaccine. “Interestingly, adults receiving three doses and those receiving one dose of BBV152 were respectively at four and two times higher risk of AESIs compared with adults receiving two doses of the Covaxin,” the BHU study said.<\/caption>\n

Agencies<\/p>\n<\/section>\n<\/div>\n


\n
Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

May 17, 2024, 04:45:52 PM IST 1\/7 BHU study on Covaxin raises alarm A one-year follow-up study by a team of researchers at BHU revealed that nearly one-third of 926 recipients of Bharat Biotech’s anti-Covid vaccine, Covaxin, reported “adverse events of special interest,” or AESI. The researchers called for an extended surveillance of COVID-19-vaccinated individuals […]<\/p>\n","protected":false},"author":2,"featured_media":53218,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"tdm_status":"","tdm_grid_status":"","fifu_image_url":"https:\/\/img.etimg.com\/thumb\/msid-110209157,width-640,resizemode-4,imgsize-23590\/bhu-study-on-covaxin-raises-alarm.jpg","fifu_image_alt":"","footnotes":""},"categories":[602],"tags":[52880,4038,52881,43163,52877,52878,52879,52875,52876,41460,14786,2086,506,250,712],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/news.talkwithrattan.com\/index.php\/wp-json\/wp\/v2\/posts\/53217"}],"collection":[{"href":"https:\/\/news.talkwithrattan.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/news.talkwithrattan.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/news.talkwithrattan.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/news.talkwithrattan.com\/index.php\/wp-json\/wp\/v2\/comments?post=53217"}],"version-history":[{"count":1,"href":"https:\/\/news.talkwithrattan.com\/index.php\/wp-json\/wp\/v2\/posts\/53217\/revisions"}],"predecessor-version":[{"id":53219,"href":"https:\/\/news.talkwithrattan.com\/index.php\/wp-json\/wp\/v2\/posts\/53217\/revisions\/53219"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/news.talkwithrattan.com\/index.php\/wp-json\/wp\/v2\/media\/53218"}],"wp:attachment":[{"href":"https:\/\/news.talkwithrattan.com\/index.php\/wp-json\/wp\/v2\/media?parent=53217"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/news.talkwithrattan.com\/index.php\/wp-json\/wp\/v2\/categories?post=53217"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/news.talkwithrattan.com\/index.php\/wp-json\/wp\/v2\/tags?post=53217"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}